3 gene ther­a­py com­pa­nies se­cure VC mon­ey; No­valis clos­es near­ly $30 mil­lion fund

A Eu­ro­pean life sci­ences VC firm will in­vest in three more star­tups spe­cial­iz­ing in rare ge­net­ic dis­eases as a part of its Sofinno­va Telethon Fund, the com­pa­ny an­nounced Wednes­day.

AA­Vant­garde Bio, Alia Ther­a­peu­tics and Borea Ther­a­peu­tics will re­ceive seed fund­ing worth a to­tal of $7.1 mil­lion. The fund is ded­i­cat­ed to biotechs in Italy, and led by Lu­cia Fac­cio and Pao­la Pozzi, Part­ners at Sofinno­va Part­ners.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN